KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Payables (2016 - 2025)

Resmed (RMD) has disclosed Payables for 16 consecutive years, with $510.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 121.66% year-over-year to $510.3 million, compared with a TTM value of $510.3 million through Dec 2025, up 121.66%, and an annual FY2025 reading of $288.1 million, up 16.33% over the prior year.
  • Payables was $510.3 million for Q4 2025 at Resmed, down from $526.7 million in the prior quarter.
  • Across five years, Payables topped out at $526.7 million in Q3 2025 and bottomed at $129.2 million in Q1 2021.
  • Average Payables over 5 years is $229.1 million, with a median of $189.4 million recorded in 2022.
  • The sharpest move saw Payables dropped 5.03% in 2023, then skyrocketed 121.66% in 2025.
  • Year by year, Payables stood at $175.4 million in 2021, then rose by 17.41% to $205.9 million in 2022, then rose by 3.1% to $212.3 million in 2023, then rose by 8.44% to $230.2 million in 2024, then soared by 121.66% to $510.3 million in 2025.
  • Business Quant data shows Payables for RMD at $510.3 million in Q4 2025, $526.7 million in Q3 2025, and $288.1 million in Q2 2025.